CML
News
Combo could target LSCs, treat CML
Image by Difu Wu Researchers say they have identified a mechanism governing malignant reprogramming of progenitors into self-renewing leukemia...
News
Expert panel issues guidelines for treatment of hematologic cancers in pregnancy
The guidelines aim to ensure that timely treatment of the cancers is not delayed in pregnant women. While rare, hematologic malignancies in...
Conference Coverage
What’s on tap at ASH 2015
Conference Coverage
NCCN unveils 'Evidence Blocks' to facilitate treatment discussions
Conference Coverage
Emerging evidence is resolving questions in CML management
Conference Coverage
CML outcomes in the age of TKIs
Major molecular response rates at 12 months were better among CML patients treated with dasatinib/nilotinib vs. imatinib for first-line therapy,...
Conference Coverage
CML: Select TKI based on comorbidities, monitor toxicity and adherence
CML treatment success is contingent on managing reversible early toxicity, adherence to therapy, achieving landmarks of response, and remaining...
News
Ponatinib’s toxicity limits use for upfront chronic phase CML
Key clinical point: The multi-tyrosine kinase inhibitor ponatinib (Iclusig) may not be suitable as first-line therapy for CML in chronic phase....
News
Chromosome 3 abnormalities linked to poor CML outcomes
News
Chromosome 3 abnormalities linked to poor CML outcomes
Conference Coverage
Variations in blood cancer survival across Europe
chemotherapy Photo by Rhoda Baer VIENNA—Results of the EUROCARE-5 study have revealed regional differences in survival for European patients with...